Central Garden & Pet: Stock Has Run Ahead of a Slowing Quarter - Wait for Proof

Rating: Hold - Wait for Q3 results before adding

Central Garden & Pet (NASDAQ: CENT) reports its fiscal 2026 third-quarter results after the close today. The stock is sitting at $44 - up 37% year-to-date and just under its 52-week high of $45.78. The consensus expects a step down in both revenue and earnings. That raises a practical question: has the multiple run ahead of the business, or does the cheap-looking valuation still have legs?

The answer right now leans toward waiting.

The quarter the market is pricing for

Analysts project Q3 EPS of $1.51, a 3% decline from the year-ago quarter. Revenue is expected around $877 million to $883 million, down roughly 9% from the prior year. Over the last 30 days, the consensus EPS estimate has been revised 50% lower. That kind of revision drift is not an accident - it reflects working-through-the-channel signals that the seasonal garden peak has shifted and consumer spending is showing softer edges.

Compare that to Q2, which was the strong quarter the stock is still partly riding. In Q2, revenue hit a record $906 million and EPS came in at $1.28 (up 8.7% year-over-year) - well above the $1.08 consensus - and operating margin expanded to 12.6% from 11.2%. Q2 also benefited from garden shipments shifting into that quarter, a timing tailwind that does not repeat.

Q3 is the natural step-down quarter. Garden demand drops as summer wanes, and pet growth - the more durable segment - may not fully offset the seasonal pullback. The market is already pricing in a softer quarter, which means a beat would have to be notable, not just adequate, to extend the rally.

What the operating numbers actually show

Look at the trailing twelve-month picture and the growth story looks thinner than the recent stock move suggests. TTM revenue growth is barely positive at 0.2%. Free cash flow - the number that matters most for a company trading at less than one times sales - fell 15% year-over-year to $282 million. The FCF margin sits at 8.9%, which is solid in absolute terms but declining at a pace worth flagging.

Margins are still structurally healthy. Gross margin is 32.2%, operating margin is 8.2%, and ROIC (return on invested capital) sits at 7.3%. Those are not weak numbers. But they describe a steady operator, not a growth accelerator. The Pet segment is the more profitable engine - it posted a 16.3% operating margin in Q2 versus 15.4% for Garden - and it's the part of the business that deserves the highest multiple. The Garden side, which is highly seasonal and more sensitive to weather and consumer confidence, drags the blended growth profile down.

Management also completed a pet distribution partnership with Phillips after Q2, retaining a 20% stake while Phillips investors took the remaining 80%. Central expects minimal EPS impact from the deal. The move simplifies the operating model and lets management focus on branded products, but it also reduces consolidated pet revenue going forward. That structural change is part of why Q3 and Q4 revenue guidance points lower.

The valuation test

Here is where the story gets nuanced. The stock trades at 15.6 times trailing earnings, 11.7 times forward earnings, and 9.4 times EV/EBITDA (enterprise value over EBITDA, which measures the price you pay relative to operating cash generation before financing and accounting charges). On those multiples alone, CENT looks cheap.

For comparison, Clorox - a fellow consumer goods name with branded products and distribution scale - trades at roughly 22 times trailing earnings and 19 times EV/EBITDA. CENT is priced at roughly half the multiple for a similar business model. The PEG ratio (price-to-earnings divided by earnings growth rate) sits at 0.34, which would normally signal deep undervaluation.

But cheap multiples on a slowing business are not always a buying opportunity. They are cheap because growth has flattened, FCF is declining, and the next two quarters are expected to show lower revenue. The forward PE of 11.7x is attractive only if earnings stabilize around the $2.70+ non-GAAP level that management has guided to for fiscal 2026. If the Phillips partnership or softer garden demand pushes full-year results below that threshold, the current multiple is not cheap enough to absorb another miss.

The balance sheet is not a concern. Central holds $653 million in cash against $1.2 billion in total debt, with a current ratio of 3.45 and gross leverage at 2.8x - below its own target range of 3.0 to 3.5x. There are no borrowings on its credit facility. The company can fund operations, buy back stock, and invest without balance sheet stress.

The catalyst clock

Today's Q3 print is the immediate catalyst. The next earnings report comes in early November for Q4 fiscal 2026. What would change the rating from Hold to Buy?

• EPS that beats the $1.51 consensus by a meaningful margin, suggesting the estimates have overshot to the downside
• Evidence that Pet segment growth is accelerating independent of seasonal Garden weakness
• Any upgrade or reaffirmation of the $2.70+ full-year EPS guidance with stronger conviction
• A sign that the Phillips partnership is generating cost savings faster than expected

What would make me more cautious?

• Revenue that falls further below the low-to-mid $880 million range, signaling demand weakness beyond seasonal timing
• Margin contraction in the Pet segment, which is the more valuable half of the business
• A full-year guidance cut
• FCF that continues its 15% decline trajectory into the next quarter

The call

Central Garden & Pet is a well-managed consumer goods company with a healthy balance sheet and a real moat in branded pet and garden products. The Phillips partnership is a rational simplification. But the stock has already moved 37% this year into a quarter that is expected to show declining revenue and earnings.

The valuation looks cheap, but the business is showing cheap-for-a-reason signals: flat TTM growth, declining FCF, and a seasonal headwind in Q3. I'm not saying the stock is overvalued. I'm saying the risk/reward has tightened after a strong run, and today's results need to do the convincing before there is a clean entry.

Hold. Wait for the Q3 print, watch the Pet segment margin trend, and reassess the full-year guidance before adding. If the stock pulls back on a missed quarter and valuation resets into single-digit EV/EBITDA territory, that would be the moment to get more interested.